0
0.5
1
1.5
2+
Mortality
15%
Improvement
Relative Risk
ICU admission
-2%
Recovery
-10%
Favipiravir Khamis et al. LATE TREATMENT RCT
Is late treatment with favipiravir + interferon beta-1b beneficial for COVID-19?
RCT 89 patients in Oman (June - August 2020)
Trial compares with HCQ, results vs. placebo may differ
Trial underpowered for serious outcomes
c19early.org
Khamis et al., Int. J. Infectious Dise.., Nov 2020
Favors favipiravir
Favors HCQ